Abstract
Interleukin-2 (IL-2) is now registered for the treatment of renal cell carcinoma in a number of European countries. The subcutaneous (sc) route of administration is being used increasingly because of its better toxicity profile compared with higher dose intravenous (iv) protocols. We report here a patient who developed a lobular panniculitis at the site of sc IL-2 injection which prevents continuation of sc therapy. Subsequent administration of the same IL-2 dose by iv injection caused recurrence of the problem again necessitating discontinuation of IL-2 treatment.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Atzpodien J., Körfer A., Franks C. R., Poliwoda H., Kirchner H. Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet. 1990 Jun 23;335(8704):1509–1512. doi: 10.1016/0140-6736(90)93039-r. [DOI] [PubMed] [Google Scholar]
- Gaspari A. A., Lotze M. T., Rosenberg S. A., Stern J. B., Katz S. I. Dermatologic changes associated with interleukin 2 administration. JAMA. 1987 Sep 25;258(12):1624–1629. [PubMed] [Google Scholar]
- Mier J. W., Aronson F. R., Numerof R. P., Vachino G., Atkins M. B. Toxicity of immunotherapy with interleukin-2 and lymphokine-activated killer cells. Pathol Immunopathol Res. 1988;7(6):459–476. doi: 10.1159/000157075. [DOI] [PubMed] [Google Scholar]
- Ramseur W. L., Richards F., 2nd, Duggan D. B. A case of fatal pemphigus vulgaris in association with beta interferon and interleukin-2 therapy. Cancer. 1989 May 15;63(10):2005–2007. doi: 10.1002/1097-0142(19890515)63:10<2005::aid-cncr2820631023>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
- Staunton M. R., Scully M. C., Le Boit P. E., Aronson F. R. Life-threatening bullous skin eruptions during interleukin-2 therapy. J Natl Cancer Inst. 1991 Jan 2;83(1):56–57. doi: 10.1093/jnci/83.1.56. [DOI] [PubMed] [Google Scholar]
- Weinstein A., Bujak D., Mittelman A., Davidian M. Erythema nodosum in a patient with renal cell carcinoma treated with interleukin 2 and lymphokine-activated killer cells. JAMA. 1987 Dec 4;258(21):3120–3121. [PubMed] [Google Scholar]